Back to Search Start Over

Optimal surgical treatment for paratesticular leiomyosarcoma: retrospective analysis of 217 reported cases

Authors :
Rei Kamitani
Kazuhiro Matsumoto
Toshikazu Takeda
Ryuichi Mizuno
Mototsugu Oya
Source :
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Publication Year :
2022
Publisher :
BMC, 2022.

Abstract

Abstract Background Paratesticular leiomyosarcoma (LMS) is a rare tumor. Conventionally, tumor resection by high inguinal orchiectomy is performed as the preferred treatment approach for paratesticular sarcoma. On the other hand, testis-sparing surgery has recently attracted attention as a less-invasive treatment option for paratesticular sarcoma. However, the prognostic predictors and optimal treatment strategy for paratesticular LMS remain unclear because of its rarity. In this study, we systematically reviewed previously reported cases of paratesticular LMS to evaluate the prognostic factors and establish the optimal treatment strategy. Methods A systematic search of Medline, Web of Science, Embase, and Google was performed to find articles describing localized paratesticular LMS published between 1971 and 2020 in English. The final cohort included 217 patients in 167 articles. The starting point of this study was the time of definitive surgical treatment, and the end point was the time of local recurrence (LR), distant metastasis (DM), and disease-specific mortality. Results Patients with cutaneous LMS had a slightly better LR-free survival, DM-free survival, and disease-specific survival than those with subcutaneous LMS (p = 0.745, p = 0.033, and p = 0.126, respectively). Patients with higher grade tumors had a significantly higher risk of DM and disease-specific mortality (Grade 3 vs Grade 1 p

Details

Language :
English
ISSN :
14712407
Volume :
22
Issue :
1
Database :
Directory of Open Access Journals
Journal :
BMC Cancer
Publication Type :
Academic Journal
Accession number :
edsdoj.709ef11ba1cd4f51adca67ea0085b32f
Document Type :
article
Full Text :
https://doi.org/10.1186/s12885-021-09122-7